Second Line Therapy and Beyond With Relacorilant and Nab-Paclitaxel for Cervical Cancer With Loss of Benefit From Immune Checkpoint and Platinum Exposure

This phase II study will evaluate the efficacy and safety of relacorilant in combination with nab-paclitaxel in participants with recurrent or metastatic cervical cancer who have previously received platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, if eligible.
STELLA is a prospective, open-label, single-arm study. Approximately 63 participants will receive relacorilant orally in combination with intravenous nab-paclitaxel in 28-day treatment cycles. Treatment will continue until disease progression, unacceptable toxicity, or another protocol-defined reason for discontinuation.
The primary objective of the study is to evaluate the objective response rate, defined as the proportion of participants with a complete or partial response as their best overall response according to RECIST version 1.1. Secondary objectives include evaluating duration of response, progression-free survival, overall survival, and the safety and tolerability of the combination.

Start Date01 Oct 2026

Sponsor / Collaborator

Arcagy-Gineco

NCT07259317

/ RecruitingPhase 2

A Phase 2, Single-Arm Trial of Relacorilant in Combination With Nab-Paclitaxel and Gemcitabine in Chemotherapy-Naïve Patients With Metastatic Pancreatic Adenocarcinoma (TRIDENT)

This is a 2-part, Phase 2 study to evaluate the safety, tolerability, dosing, pharmacokinetics (PK), and efficacy of relacorilant in combination with nab-paclitaxel and gemcitabine in chemotherapy-naïve patients with metastatic pancreatic adenocarcinoma (PDAC).

Start Date27 Jan 2026

Sponsor / Collaborator

Corcept Therapeutics, Inc.

NCT06906341

/ RecruitingPhase 2

An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers (BELLA)

This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

Start Date11 Apr 2025

Sponsor / Collaborator

Corcept Therapeutics, Inc.

100 Clinical Results associated with Relacorilant

100 Translational Medicine associated with Relacorilant

100 Patents (Medical) associated with Relacorilant

Literatures (Medical) associated with Relacorilant

23 Apr 2026·JOURNAL OF MEDICINAL CHEMISTRY

Development of Structurally Simplified, Non-azadecalin Glucocorticoid Antagonists which Demonstrate In Vivo Activity

Article

Author: Hornsby, Thomas W. ; Lee, Sally L. ; Hunt, Hazel J. ; Jouanneau, Morgan ; Duffy, Lorna A. ; Peall, Adam P. ; Waszkowycz, Bohdan ; Bali, Utsav ; Mills, Mark T. ; Phillips, Andrew W. ; Strutt, Ian R. ; Walters, Iain A. S.

Glucocorticoid receptor antagonists (GR antagonists) are a class of compounds developed to inhibit the activation of the glucocorticoid receptor and they have been used to treat a range of conditions such as Cushing's syndrome, diabetes, glaucoma, and depression. We report herein the discovery and optimization of a series of selective piperazine-based GR antagonists and discuss how key learnings from the discovery of relacorilant (CORT125134) were utilized to identify a simplified scaffold. Several compounds were identified with the desired profile and 3 key compounds were progressed to in vivo proof of concept studies.

01 Apr 2026·LANCET

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial

Article

Author: Jubb, Adrian M ; Santaballa, Ana ; Diakos, Connie ; Prillaman, Christina ; Hopp, Elizabeth ; Garbaos, Gabriel ; Artioli, Grazia ; Gavoille, Laurène ; Oaknin, Ana ; Cassani, Chiara ; Mileshkin, Linda ; Monk, Bradley J ; Follana, Philippe ; Tudor, Iulia Cristina ; Leiser, Aliza L ; Scaranti, Mariana ; Slomovitz, Brian ; Van Gorp, Toon ; Olawaiye, Alexander B ; Bagaméri, Andrea ; Gladieff, Laurence ; Colombo, Nicoletta ; Lee, Yong Jae ; O'Malley, David M ; Salutari, Vanda ; Quesada, Stanislas ; Kesner-Hays, Amanda ; Carbone, Vittoria ; Cannizzaro, Maria Chiara ; Giudice, Elena ; Scandurra, Giuseppa ; Kim, Jae-Weon ; McClung, Emily ; Dreiling, Lyndah K ; Clamp, Andrew ; Devaux, Alix ; Scollo, Paolo ; Gilbert, Lucy ; Lorusso, Domenica ; Fagotti, Anna ; Kim, Byoung-Gie

BACKGROUND:

Relacorilant is a selective glucocorticoid receptor antagonist that increases the sensitivity of many cancer cell types to chemotherapy. The efficacy and safety of relacorilant plus nab-paclitaxel were assessed in the phase 3 ROSELLA (GOG-3073, ENGOT-ov72, APGOT-Ov10, and LACOG-0223) trial; the combination showed significant improvement in progression-free survival among patients with platinum-resistant ovarian cancer compared with nab-paclitaxel monotherapy. Results of the final overall survival analysis are reported here.

METHODS:

In this open-label phase 3 trial, patients were randomly assigned 1:1 to receive relacorilant (150 mg orally the day before, day of, and day after nab-paclitaxel infusion) plus nab-paclitaxel (80 mg/m² intravenously on days 1, 8, and 15 of each 28-day cycle) or nab-paclitaxel monotherapy (100 mg/m² intravenously on the aforementioned schedule). Patients, aged 18 years or older, with one to three lines of previous anticancer therapy and platinum-resistant disease (progression <6 months from their last dose of platinum) were eligible. The trial was conducted at 117 hospitals and community oncology centres in 14 countries across Australia, Europe, Latin America, North America, and South Korea. Progression-free survival, assessed by blinded independent central review, and overall survival (time from randomisation to death from any cause) were dual primary endpoints. Additional prespecified endpoints included safety, second progression-free survival (time from randomisation to disease progression on subsequent anticancer therapy or death due to any cause, whichever occurred first), and patient-reported outcomes. This trial is registered at ClinicalTrials.gov, NCT05257408, and is ongoing.

FINDINGS:

Between Jan 5, 2023, and April 8, 2024, 381 patients were randomly assigned to the relacorilant combination group (n=188) or the nab-paclitaxel monotherapy group (n=193). All patients had received bevacizumab; 167 (44%) had received three previous lines of therapy, and 234 (61%) had received a poly(ADP-ribose) polymerase inhibitor. At a median follow-up of 24·8 months (95% CI 23·6-25·7), the addition of relacorilant to nab-paclitaxel resulted in a statistically and clinically significant improvement in overall survival compared with nab-paclitaxel monotherapy (hazard ratio for death 0·65 [95% CI 0·51-0·83]; p=0·0004); 18-month overall survival was 46% and 27%, respectively. The median overall survival in the relacorilant combination group was extended by 4·1 months compared with the nab-paclitaxel monotherapy group (16·0 [95% CI 13·0-18·3] vs 11·9 months [10·0-13·8]). Subsequent anticancer treatments were similar across study groups. Adverse events were similar in both groups when adjusted for duration of study treatment. Neutropenia (121 [64%]), anaemia (115 [61%]), fatigue (101 [54%]), and nausea (82 [44%]) were the most common adverse events in the relacorilant combination group. No new safety signals were observed with additional follow-up since the primary analysis.

INTERPRETATION:

The addition of relacorilant to nab-paclitaxel led to significantly longer overall survival in patients with platinum-resistant ovarian cancer, without the need for biomarker selection. The findings support relacorilant plus nab-paclitaxel as a potential new standard treatment option for patients with platinum-resistant ovarian cancer.

FUNDING:

Corcept Therapeutics.

01 Apr 2026·Lancet Diabetes & Endocrinology

Efficacy and safety of relacorilant for the treatment of patients with Cushing's syndrome (GRACE): a multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study

Article

Author: Bourdeau, Isabelle ; Mathews, Joseph W ; Fazeli, Pouneh K ; Al-Karadsheh, Amer ; Elenkova, Atanaska ; Recasens, Monica ; Nya-Ngatchou, Jean J ; Yuen, Kevin C J ; Arnaldi, Giorgio ; Busch, Robert ; Sachmechi, Isaac ; Chmiel-Perzyńska, Iwona ; Feelders, Richard A ; Dresner-Pollak, Rivka ; Stigliano, Antonio ; Kirschner, Lawrence S ; Miller, Harold J ; Tudor, Iulia Cristina ; Abbott, Lisa ; Ownby, Jonathan ; Hannoush, Zeina C ; Auchus, Richard J ; Romanowski, Leszek ; Ranetti, Aurelian-Emil ; Hannoush, Zeina ; East, Honey E ; Silverstein, Julie ; Kargi, Atil Y ; Salvatori, Roberto ; Fassnacht, Martin ; Jabbour, Serge ; Araque, Katherine A ; Katselnik, Daniel ; Shimon, Ilan ; Wang, Christina ; Huang, Wenyu ; Geer, Eliza ; Rotman-Pikielny, Pnina ; Reincke, Martin ; Gordon, Murray B ; Aresta, Carmen ; Fazeli, Pouneh ; Badiu, Corin ; Moraitis, Andreas G ; Hamidi, Oksana ; Dobri, Georgiana ; Dobri, Georgiana A ; Donegan, Diane M ; Kesner-Hays, Amanda ; Garcia-Centeno, Rogelio ; Niculescu, Dan ; Preda, Cristina ; Terzolo, Massimo ; Dischinger, Ulrich ; Cannavò, Salvatore ; Pivonello, Rosario ; Drincic, Andjela ; Greenman, Yona ; Scaroni, Carla ; Miller, Harold ; Martino, Marianna ; Hand, Austin L ; Isidori, Andrea ; Gilis-Januszewska, Aleksandra ; Maduerio, Francisco JT ; Min, Le ; Heaney, Anthony ; Parker, John C ; Imran, Syed A ; Levine, Alice ; Lim, Jonea ; Rovner, Sergio ; Picó Alfonso, Antonio M ; Soto-Moreno, Alfonso ; Busch, Robert S ; Kautzky-Willer, Alexandra ; Donegan, Diane ; Rovner, Sergio S ; Yuen, Kevin CJ

BACKGROUND:

Relacorilant is a selective glucocorticoid receptor modulator designed to reduce excess cortisol activity by competing with cortisol for glucocorticoid receptor binding, mitigating the clinical manifestations of endogenous hypercortisolism (Cushing's syndrome). The aim of this study was to assess the efficacy and safety of relacorilant in adults with endogenous hypercortisolism.

METHODS:

This multicentre, phase 3, double-blind, placebo-controlled, randomised-withdrawal study enrolled adults with endogenous hypercortisolism and hypertension, hyperglycaemia, or both and was conducted at 77 study centres across 11 countries. Key inclusion criteria included being aged 18-80 years with at least two clinical signs or symptoms of hypercortisolism. In the open-label phase, patients received oral, once-daily relacorilant (escalation from 100 mg up to 400 mg) for 22 weeks. Patients who met response criteria were randomly assigned (1:1) by the interactive web response system to continue relacorilant 400 mg (or highest tolerated dose) or placebo for 12 weeks in the randomised-withdrawal phase. Participants and investigators were masked to treatment assignment. The primary outcome was the proportion of patients who lost hypertension response during the randomised-withdrawal phase compared between relacorilant and placebo at week 12. As per protocol, this outcome was assessed in all participants who received at least one dose of study drug in the study period (intention-to-treat population). Missing randomised-withdrawal week 12 values were considered a loss of response. Safety was assessed in all enrolled patients who received at least one dose of study drug in that period. This study is registered with ClinicalTrials.gov, NCT03697109.

FINDINGS:

Between Oct 16, 2018, and April 15, 2024, 404 patients were screened, 152 were enrolled, and 95 completed the open-label relacorilant phase. 62 patients met response criteria and were randomly assigned to relacorilant (30 total participants [21 met hypertension response criteria]) or placebo (32 total participants [22 met hypertension response criteria]). In the 30 participants in the relacorilant group, the mean age was 46·6 years (SD 11·0), 22 (73%) were female, and eight (27%) were male. In the 32 participants in the placebo group, the mean age was 48·8 years (SD 14·4), 26 (81%) were female, and six (19%) were male. During the randomised-withdrawal phase, significantly more patients with baseline hypertension who were randomly assigned to placebo lost hypertension control compared with those who continued relacorilant (proportion difference 34%; odds ratio 0·17 [95% CI 0·04-0·77]; p=0·022). In the randomised-withdrawal phase safety population, the most common adverse events in the 30 participants given relacorilant and the 32 participants given placebo were back pain (5 [17%] vs 6 [19%]), acne (3 [10%] vs 0), arthralgia (3 [10%] vs 3 [9%]), bursitis (3 [10%] vs 0), headache (3 [10%] vs 4 [13%]), and insomnia (0 vs 4 [13%]). There were no cases of excessive glucocorticoid receptor antagonism, adrenal insufficiency, vaginal bleeding associated with endometrial hypertrophy, drug-induced hypokalaemia, or drug-induced QT interval prolongation.

INTERPRETATION:

Patients treated with relacorilant were more likely to maintain hypertension control compared with patients treated with placebo. The findings support consideration of relacorilant as a therapeutic option to reduce the harmful and debilitating effects of endogenous hypercortisolism.

FUNDING:

Corcept Therapeutics.

News (Medical) associated with Relacorilant

18 Sep 2026

·www.fiercepharma.com

Europe's CHMP endorses slew of new medicines, including new offerings from Novo and AZ

European drug regulators just wrapped another stack of reviews , and the EU bloc now has a sizeable list of likely new treatments to show for it. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has signed off on eight new medicines, two biosimilars and two generics, while also recommending label extensions for 11 other therapies. Among the most notable developments is a positive recommendation for Novo’s Frehemgo, also known as denecimig, to treat or prevent bleeding episodes in adults and children with hemophilia A. Novo is positioning the drug as a next-generation factor VIIIa mimetic. The bispecific antibody works by binding Factor IXa and Factor X to increase thrombin production and improve clotting. Frehemgo is in direct competition with Roche’s blockbuster and current market leader Hemlibra, which made 4.8 billion Swiss francs ($5.81 billion) in sales last year. The CHMP recommendation comes just days after Frehemgo’s first approval in Saudi Arabia and makes way for a possible approval from the European Commission in the coming weeks. It’s a welcome win for Novo after suffering a string of late-stage disappointments in its cardiovascular pipeline amid mounting competition in metabolic medicine markets. The Danish drugmaker expects an initial launch of Frehemgo by years' end, with a broader rollout in early 2027. AstraZeneca’s rare disease business Alexion also snagged a recommendation from the CHMP, setting up dual-binding nanobody C5 inhibitor Klygefa for a formal approval from the EC. Klygefa, also known as gefurulimab, received the CHMP go-ahead as a treatment for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune disease marked by muscle weakness caused by the immune system’s attack on the connection points between the nerves and muscles. The treatment marks AstraZeneca’s continued investment in the C5 inhibitor class after Soliris and Ultomiris. But unlike those earlier infused drugs, Klygefa is a self-administered injection, offering patients more control and flexibility. If approved, Europe will be Klygefa’s second approval after Japan earlier this month and it will be the first dual-binding nanobody C5 inhibitor approved for gMG patients. Beyond those meds, new offerings from SFL Pharmaceuticals, Corcept, Incyte Biosciences and Sanofi also made the cut at CHMP this week. SFL scored double with a positive recommendation for both Gevalka and Sepalna. Gevalka was recommended in adults with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer, a version of the disease more common in young patients who have never smoked. And Sepalna was recommended as a maintenance treatment of advanced epithelial high-grade ovarian, fallopian tube, or primary perineal cancer. Corcept’s Lifyorli, meanwhile, snagged a recommendation as a combo treatment with chemotherapy for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Incyte Biosciences’ Povofortay will take a positive review to the European Commission for acne inversa. And rounding out the list of endorsements was Sanofi’s rabies vaccine VaxRabeo. Alfasigma’s Jyseleca, AstraZeneca and Daiichi Sankyo's Enhertu, Merk & Co.'s Keytruda, Novartis’ Cosentyx, Leo’s Anzupgo, and Roche’s Ocrevus, among others, took positive opinions for their proposed label expansions. In a setback for MaaT Pharma, the CHMP elected—after reexamination—to uphold its decision to recommend against Xervyteg as a treatment for acute graft-versus-host disease, a life-threatening condition in which donor bone marrow or stem cells attack the patient. The agency maintained that MaaT’s single-arm trial did not show a sufficient benefit-risk profile. In response, the pharma proposed a phase 3 trial evaluating Xervyteg against a best available therapy to satisfy regulator concerns. All CHMP recommendations now head for the European Commission for final sign-off.

Drug ApprovalPhase 3Clinical Result

18 Sep 2026

·firstwordpharma.com

Novo's Frehemgo, Incyte's Povofortay among key CHMP nods in September

The EMA's drug advisory panel backed a dozen new medicines for approval at its September meeting, including Novo's Frehemgo (denecimig) for haemophilia A, Incyte's Povofortay (povorcitinib) in severe hidradenitis suppurativa (HS) and two therapies for ovarian cancer.Among the more closely watched decisions announced Friday, the agency's Committee for Medicinal Products for Human Use (CHMP) recommended Frehemgo for the routine prophylaxis of bleeding episodes in patients with haemophilia A, regardless of inhibitor status. The decision was supported by findings from the FRONTIER programme, in which Frehemgo significantly reduced the annualised bleeding rate compared to prior clotting factor prophylaxis and on-demand treatment. The next-generation factor VIIIa mimetic bispecific antibody, previously known as Mim8, has also shown comparable effectiveness in children.The drug's dosing flexibility – it can be given once-monthly, once every two weeks, or once-weekly via single-use pre-filled pens – could be a possible key differentiator (see — KOL Views Q&A: Novo Nordisk’s denecimig may struggle to displace entrenched Hemlibra in haemophilia A). A similar application for Frehemgo is under review in the US.On Friday, Novo also received a positive CHMP opinion to expand use of Sogroya (somapacitan) to include children living with idiopathic short stature with persistent growth disturbance. The once-weekly, long-acting human growth hormone analogue is already authorised in the EU for the treatment of growth hormone deficiency in adults and in children ages 3 years and older.Povofortay nears first OKMeanwhile, the positive opinion for Povofortay moves Incyte's oral JAK1 inhibitor one step closer to securing its first approval. CHMP's decision covers the treatment of active moderate-to-severe HS in adults who have responded inadequately to, or who are intolerant or contraindicated to an anti-TNF therapy.The submission is supported by findings from the Phase III STOP-HS1 and STOP-HS2 studies, which both met their primary endpoints by demonstrating significant reductions in abscess and nodule count. Longer-term results presented at this year's American Academy of Dermatology (AAD) meeting showed that up to 57% of HS patients taking Povofortay achieved ≥75% reduction in inflammatory lesions after one year in the trials.A filing in this indication is also under review in the US, while Incyte is planning applications in vitiligo based on data released earlier this year. Pair of ovarian cancer drugsIn ovarian cancer, CHMP backed the approval of drugs with two different mechanisms of action: Corcept Therapeutics' selective glucocorticoid receptor modulator Lifyorli (relacorilant) and IMPACT Therapeutics' oral PARP1/2 inhibitor Sepalna (senaparib).Lifyorli's positive opinion is for use in combination with nab-paclitaxel to treat platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. The drug, which was approved earlier this year in the US, is seen as an advancement in ovarian cancer treatment. Deanna Gerber, an assistant professor of obstetrics and gynaecology at Weill Cornell Medicine, previously told FirstWord that Lifyorli is "going to be the next big thing" in the field (see – KOL Views Q&A: Relacorilant set for early uptake in platinum-resistant ovarian cancer).The recommendation was based on clinical data including from the Phase III ROSELLA trial, in which patients given Lifyorli plus nab-paclitaxel achieved improved progression-free and overall survival compared to nab-paclitaxel alone, without an increase in adverse events.The EMA panel also endorsed Sepalna as a maintenance treatment for advanced epithelial ovarian, fallopian tube and primary peritoneal cancer. The decision was supported by findings from the Phase III FLAMES study, in which Sepalna reduced the risk of disease progression of death by 57% compared to placebo when used as first-line maintenance monotherapy in a broad patient population with advanced ovarian cancer.Sepalna is already approved in China in the ovarian cancer maintenance setting, while IMPACT recently out-licensed certain rights to the drug to Pharmanovia, including in the EU.Other new drugs recommended for approval at CHMP's latest meeting include Xcovery's Gevalka (ensartinib) for adults with ALK-positive advanced non–small-cell lung cancer, AstraZeneca's Klygefa (gefurulimab) for generalised myasthenia gravis, Sanofi's rabies vaccine VaxRabeo, and Zealand Pharma's Zeydovio (glepaglutide) for the treatment of short bowel syndrome.

Clinical ResultPhase 3Drug Approval

18 Sep 2026

·www.biospace.com

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety pro relacorilant plus nab-paclitaxel in these trials was consistent with the safety pro nab-paclitaxel monotherapy. The EC will review the CHMP's opinion and issue a final decision regarding approval in the fourth quarter of 2026. “The CHMP’s positive opinion takes us a big step closer to making the benefits of glucocorticoid receptor antagonism available to patients in the EU. We look forward to the European Commission’s final decision,” said Joseph K. Belanoff, M.D., Corcept’s Chief Executive Officer. “I want to thank the CHMP for conducting such an efficient and timely review. I also want to thank the healthcare providers and patients who participated in relacorilant’s clinical trials. Without them, advancing this fundamentally new approach to treating cancer would not have been possible.” About Relacorilant Relacorilant achieves its effects by binding to the glucocorticoid receptor but not to the body’s other hormone receptors. Relacorilant is the only selective glucocorticoid receptor modulator approved by the U.S. Food and Drug Administration for any indication. It is marketed in the United States for the treatment of patients with platinum-resistant ovarian cancer under the trade name Lifyorli ® . Relacorilant is proprietary to Corcept and is protected by composition of matter, method of use, formulation, manufacturing and other patents. About the ROSELLA Pivotal Trial ROSELLA was relacorilant’s pivotal Phase 3 trial. It enrolled 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone. The ROSELLA trial is being conducted in collaboration with the GOG Foundation, Inc., the European Network of Gynaecological Oncological Trial groups, the Asia-Pacific Gynecologic Oncology Trials Group, the Latin American Cooperative Oncology Group and the Australia New Zealand Gynaecological Oncology Group. About Ovarian Cancer Ovarian cancer is the fifth most common cause of cancer death in women. Patients with disease that progresses less than six months after commencing platinum-based chemotherapy have “platinum-resistant” disease. There are few treatment options for these women. Approximately 20,000 women with platinum-resistant disease are candidates to start a new therapy each year in the United States, with at least an equal number in Europe. About Cortisol's Role in Oncology Cortisol plays a role in tumor growth through several mechanisms. It helps solid tumors resist chemotherapy by inhibiting cellular apoptosis — the tumor-killing effect chemotherapy is meant to stimulate. In some cancers, cortisol promotes tumor growth by activating oncogenic signaling in the cells to which it binds. Cortisol also suppresses the body's immune response, which weakens its ability to fight all diseases, including cancer. About Corcept Therapeutics For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced development programs in patients with hypercortisolism, a variety of solid tumors, ALS and liver disease. Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations and are subject to risks and uncertainties that might cause our actual results to differ materially from any future results expressed or implied by such forward-looking statements. In this press release, forward-looking statements include statements concerning: relacorilant’s safety pro potential as a treatment for patients with platinum-resistant ovarian cancer; the anticipated timing and outcome of the EC’s review of the CHMP opinion, including the potential for the EC to approve our marketing application in the fourth quarter of 2026; and Corcept’s intent to make the benefits of glucocorticoid receptor antagonism available to patients in the EU. A further description of risks and uncertainties affecting our forward-looking statements can be found in our SEC filings, which are available at our website and the SEC’s website. These risks and uncertainties include, but are not limited to, those related to: our ability to operate our business; our efforts to study and develop Korlym, Lifyorli, relacorilant, miricorilant, dazucorilant, nenocorilant and our other product candidates; those molecules’ clinical attributes; regulatory approvals, mandates, oversight and other requirements imposed on our products or our business by laws, regulations or discretion of government authorities; and the scope and protective power of our intellectual property. We disclaim any intention or duty to update forward-looking statements made in this press release. Contacts Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com

Phase 3Clinical ResultDrug Approval

100 Deals associated with Relacorilant

External Link

KEGG	Wiki	ATC	Drug Bank
D11336	Relacorilant	-	DB14976

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Platinum-Resistant Epithelial Ovarian Carcinoma	United States	Corcept Therapeutics, Inc.	25 Mar 2026
Platinum-Resistant Fallopian Tube Carcinoma	United States	Corcept Therapeutics, Inc.	25 Mar 2026
Platinum-Resistant Primary Peritoneal Carcinoma	United States	Corcept Therapeutics, Inc.	25 Mar 2026

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Platinum-Resistant Ovarian Carcinoma	NDA/BLA	United States	Corcept Therapeutics, Inc.	14 Jul 2025
Cushing Syndrome	NDA/BLA	United States	Corcept Therapeutics, Inc.	30 Dec 2024
Adrenocortical Adenoma	Phase 3	United States	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Austria	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Bulgaria	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Germany	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Israel	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Italy	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Poland	Corcept Therapeutics, Inc.	27 Jul 2020
Adrenocortical Adenoma	Phase 3	Romania	Corcept Therapeutics, Inc.	27 Jul 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2026	Not Applicable	Platinum-Resistant Ovarian Carcinoma	4	Relacorilant plus nab-paclitaxel (platinum-resistant ovarian cancer)	ksxwyffflg(ueaijixyai) = Safety analyzes revealed no significant difference between the groups in the risk of anemia (RR 1.02, 95% CI 0.66 to 1.59, I2 = 8.9%) unesvyjzxs (akvruidnhh ) View more	Positive	29 May 2026
				Nab-paclitaxel (platinum-resistant ovarian cancer)
NCT07259317 (TRIDENT, ASCO2026)	Phase 2	Metastatic Pancreatic Ductal Adenocarcinoma First line	60	Relacorilant + nab-paclitaxel + gemcitabine	yihsysqjrh(fjwuflidha) = vebpmapbej aytecbfmwp (gvauhgpwbg, 24.95 - NR) View more	Positive	29 May 2026
NCT05257408 (ROSELLA, Pubmed \| Lancet)	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + Nab-paclitaxel	teorpcoeoa(llfwidynur) = Neutropenia (121 [64%]), anaemia (115 [61%]), fatigue (101 [54%]), and nausea (82 [44%]) were the most common adverse events in the relacorilant combination group. cjdqiibzfj (zkahxkzxzm )	Positive	01 Apr 2026
				Nab-paclitaxel
ROSELLA (ESGO2026)	Phase 3	Platinum-Resistant Ovarian Carcinoma	234	Relacorilant + nab-paclitaxel	eukgvvkjrx(idopaqibsv) = ijfcyojzyn iblmaxpkrm (omczbwlcog, 5.38 - 9.53) View more	Positive	28 Feb 2026
				nab-paclitaxel	jyrdlkkeul(hutkbshnes) = jtdredwgay okqcjpicxt (wtfxnloztj ) View more
NCT05726292 (ASCO_GU2026)	Phase 2	Localized Prostate Carcinoma Neoadjuvant	90	LHRH agonist/antagonist + Enzalutamide + Relacorilant	vykcjnwdvb(hqwjsdvkps): P-Value = 0.15 View more	Positive	26 Feb 2026
				LHRH agonist/antagonist + Enzalutamide + Placebo
NCT04308590 (GRADIENT, CTgov)	Phase 3	Cushing Syndrome \| Adrenocortical Adenoma	137	Placebo+Relacorilant (Relacorilant)	yrqptpmaug(cvbglslwlt) = ytapdebgfd rczgsqcrjw (vfpnoukseh, bmofsrewte - ijdekjckte) View more	-	03 Aug 2025
				Placebo (Placebo)	yrqptpmaug(cvbglslwlt) = fkgrvqyjva rczgsqcrjw (vfpnoukseh, ntklaqykqm - ksjpohchjx) View more
NCT03697109 (GRACE, ENDO2025)	Phase 3	Cushing Syndrome	152	Relacorilant 100 mg to 400 mg once daily	lqwwwrbnxj(vxskwfowhd) = Relacorilant was well-tolerated and effective at improving hypertension and hyperglycemia parameters in this study. tscdqakttn (hbiqmxxsyy )	Positive	12 Jul 2025
NCT03697109 (GRACE, ENDO2025)	Phase 3	Cushing Syndrome	97	Relacorilant	gcjaxbvjpj(qilnngwepf) = ykgvlcxzau stiidmohvj (dzevuirbkk ) View more	Positive	12 Jul 2025
				Placebo	gcjaxbvjpj(qilnngwepf) = vprtstbjtn stiidmohvj (dzevuirbkk ) View more
NCT03697109 (GRACE, ENDO2025)	Phase 3	Cushing Syndrome	152	Relacorilant 100-400 mg QD	dbrktfjzfk(nzzbgjinoe) = cqtbkjjkeo qamqebfjkx (mmeiglhpst ) View more	Positive	12 Jul 2025
				Placebo	yxmpqnswpt(gsqqzehsty) = cfzvrucsfa xafjthherf (isvweizjcf ) View more
NCT05257408 (ROSELLA \| GOG-3073 \| ENGOT-ov72, ESMO_GCC2025)	Phase 3	Platinum-Resistant Ovarian Carcinoma	381	Relacorilant + nab-paclitaxel	ahrptaefhu(lsnaxkwdmg) = ggewedqvvn qtsgvwdadl (ymxyamelim ) View more	Positive	19 Jun 2025
				nab-paclitaxel	ahrptaefhu(lsnaxkwdmg) = ndngniopac qtsgvwdadl (ymxyamelim ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis